Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

This summary is generated by an algorithm. If you find any mistakes, let us know.

GenEdit Announces Series A Financing and Provides Research Update at TIDES 2021
GenEdit Announces Series A Financing and Provides Research Update at TIDES 2021
UN

Unicorn Nest news

GenEdit Announces Series A Financing and Provides Research Update at TIDES 2021

– GenEdit has closed a $26m Series A financing.
– New investors include Eli Lilly, KTB Network, Company K Partners, Korea Investment Partners, DAYLI Partners, KB Investment, IMM Investment, and TIMEFOLIO Asset Management.
– The funding will support the further development of GenEdit’s NanoGalaxy™ platform of non-viral, non-lipid polymer nanoparticles, and the selection for clinical development of therapeutic candidates targeting diseases of the nervous system.

Source
Revenue-based financing startup Jenfi raises $6.3M to focus on high-growth Southeast Asian companies
Revenue-based financing startup Jenfi raises $6.3M to focus on high-growth Southeast Asian companies
UN

Unicorn Nest news

Revenue-based financing startup Jenfi raises $6.3M to focus on high-growth Southeast Asian companies

– Jenfi, a Singapore-based startup, raised $6.3m in Series A funding.
– The round was led by Monk’s Hill Ventures and joined by Korea Investment Partners, Golden Equator Capital, 8VC, ICU Ventures and Taurus Ventures.
– The company previously raised $25m in debt financing from San Francisco-based Arc Labs.
– Jenfi works primarily with “digital-native” companies, including SaaS providers and e-commerce sellers.
– It claims that the average Jenfi customer experienced compounded sales growth of about 26.5% over three months, 60% over six months and 156% over 12 months.

Source
S-Alpha Therapeutics, Inc., Digital Therapeutics Start-up Raises $8.7 Million in Series A Funding
S-Alpha Therapeutics, Inc., Digital Therapeutics Start-up Raises $8.7 Million in Series A Funding
UN

Unicorn Nest news

S-Alpha Therapeutics, Inc., Digital Therapeutics Start-up Raises $8.7 Million in Series A Funding

– S-Alpha Therapeutics announced the completion of its Series A financing.
– The company raised a total of $8.7M USD (10 Billion KRW) in financing round.
– In Series A funding, all existing investors participated in this investment, and Korea Investment Partners, Stonebridge Ventures, Devsisters Ventures/KDB Capital, and Timewise Investment participated as new investors.

Source
Eyevensys Raises $12M in a Series B Plus Funding Round
Eyevensys Raises $12M in a Series B Plus Funding Round
UN

Unicorn Nest news

Eyevensys Raises $12M in a Series B Plus Funding Round

– Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, announces it has raised $12M in a Series B Plus funding round.
Korea Investment Partners is leading the Series B Plus financing and existing investors will also join the round.
– The financing will support Eyevensys’ accelerated development of its EYS809 program for the treatment of wet age-related macular degeneration (AMD), a chronic eye disorder that causes blurred vision or a blind spot in the eye. The condition accounts for approximately 90 percent of all AMD-related blindness. Additionally, the company will advance its EYS611 program targeting geographic atrophy (GA) and retinitis pigmentosa.

Source
Geneos Therapeutics Raises $12M in Series A1 Financing
Geneos Therapeutics Raises $12M in Series A1 Financing
UN

Unicorn Nest news

Geneos Therapeutics Raises $12M in Series A1 Financing

– Geneos Therapeutics from Plymouth Meeting, Pa. develops personalized neoantigen-targeting immunotherapies for cancer.
– The company raised $12m in Series A1 funding.
– The round was led by Korea Investment Partners (KIP) – Global Bio Fund with participation from existing investors Santé Ventures and Inovio Pharmaceuticals, Inc. (NASDAQ: INO).
– The company plans to use the funds for the expansion of the company’s:
– GT-30 Phase Ib/IIa clinical trial evaluating its personalized neoantigen-targeting vaccine,

Source
1 2 3 58 59 60
Crunchbase icon

Content report

The following text will be sent to our editors: